4-Bromo-2-(4-fluorophenyl)-1-(2-[1-(S)-phenylethyl]amino-4-pyrimidyl)imidazole | 302838-67-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 4-Bromo-2-(4-fluorophenyl)-1-(2-[1-(S)-phenylethyl]amino-4-pyrimidyl)imidazole
• 英文别名: 4-Bromo-2-(4-fluoropenyl)-1-(2-[1-(S)-phenylethyl]amino-4-pyrimidyl)imidazole；4-[4-bromo-2-(4-fluorophenyl)imidazol-1-yl]-N-[(1S)-1-phenylethyl]pyrimidin-2-amine
• CAS: 302838-67-1
• 化学式: C₂₁H₁₇BrFN₅
• 分子量: 438.302
• InChiKey: FAXGTGUOQXVMMD-AWEZNQCLSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.3
• 重原子数：
  28
• 可旋转键数：
  5
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.1
• 拓扑面积：
  55.6
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  三甲基(4-吡啶基)锡 、 4-Bromo-2-(4-fluorophenyl)-1-(2-[1-(S)-phenylethyl]amino-4-pyrimidyl)imidazole 在 PdCl2(PPh3)2 作用下， 以68%的产率得到2-(4-Fluorophenyl)-1-(2-[1-(S)-phenyl-ethyl]amino-4-pyrimidyl) 4-(4-pyridyl)-imidazole
  参考文献：
  名称：

  Substituted azoles

  摘要：

  其中符号具有本文所定义的含义，是p38 MAP激酶抑制剂，并在药学上用于治疗由TNF&agr;和IL-1介导的疾病，如类风湿关节炎，以及骨代谢疾病，例如骨质疏松症。

  公开号：

  US20020049220A1
• 作为产物：
  描述：

  4-Bromo-2-(4-fluorophenyl)-1-H-imidazole 在 双(三甲基硅烷基)氨基钾 、 间氯过氧苯甲酸 作用下， 以 二氯甲烷 、 甲苯 为溶剂， 反应 24.33h， 生成 4-Bromo-2-(4-fluorophenyl)-1-(2-[1-(S)-phenylethyl]amino-4-pyrimidyl)imidazole
  参考文献：
  名称：

  Novel p38 inhibitors with potent oral efficacy in several models of rheumatoid arthritis

  摘要：

  A library of trisubstituted oxazoles, thiazoles, imidazoles (1,2,4- and 2,4,5-substituted) and imidazo[1,2-b]pyridines was prepared and evaluated in vitro as p38alpha inhibitors and in vivo in several models of rheumatoid arthritis. Four structures 32, 37, 45 and 59-were identified as potent inhibitors of p38alpha with high efficacy in the LPS induced TNFalpha release model in the mouse, the adjuvant induced arthritis and the collagen induced arthritis in the rat with ED(50)s between 1.0 and 9.5 mg/kg p.o. (C) 2004 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2004.03.106

文献信息

• SUBSTITUTED AZOLES
  申请人：Novartis AG

  公开号：EP1224180B1

  公开（公告）日：2003-07-02
• US6579874B2
  申请人：——

  公开号：US6579874B2

  公开（公告）日：2003-06-17
• Substituted azoles
  申请人：——

  公开号：US20020049220A1

  公开（公告）日：2002-04-25

  1 wherein the symbols have meaning as defined herein, are p38 MAP kinase inhibitors, and are useful pharmaceutically for treating TNF&agr; and IL- 1 mediated diseases, such as rheumatoid arthritis, and diseases of bone metabolism, e.g. osteoporosis.

  其中符号具有本文所定义的含义，是p38 MAP激酶抑制剂，并在药学上用于治疗由TNF&agr;和IL-1介导的疾病，如类风湿关节炎，以及骨代谢疾病，例如骨质疏松症。
• Novel p38 inhibitors with potent oral efficacy in several models of rheumatoid arthritis
  作者：Laszlo Revesz、Ernst Blum、Franco E. Di Padova、Thomas Buhl、Roland Feifel、Hermann Gram、Peter Hiestand、Ute Manning、Gerard Rucklin

  DOI：10.1016/j.bmcl.2004.03.106

  日期：2004.7

  A library of trisubstituted oxazoles, thiazoles, imidazoles (1,2,4- and 2,4,5-substituted) and imidazo[1,2-b]pyridines was prepared and evaluated in vitro as p38alpha inhibitors and in vivo in several models of rheumatoid arthritis. Four structures 32, 37, 45 and 59-were identified as potent inhibitors of p38alpha with high efficacy in the LPS induced TNFalpha release model in the mouse, the adjuvant induced arthritis and the collagen induced arthritis in the rat with ED(50)s between 1.0 and 9.5 mg/kg p.o. (C) 2004 Elsevier Ltd. All rights reserved.